The Business Of Biotech Podcast
-
Innovating On The Frontier Of Radiopharmaceuticals With RadioMedix's Ebrahim Delpassand, M.D.
7/23/2025
On this week's Business of Biotech episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing a radiopharmaceutical company focused on oncology.
-
Building An Efficient Biopharma With South Rampart Pharma's Hernan Bazan, M.D.
7/16/2025
On this week's Business of Biotech, Dr. Hernan Bazan, M.D., co-founder and CEO at New Orleans-based South Rampart Pharma, talks about building an ultra-lean drug development company to address an unmet need observed in his own patients as a surgeon: safe treatments for acute pain.
-
The Business And Science Of Obesity With Roger Cone, Ph.D., Founder Of Courage Therapeutics
7/9/2025
On this week's episode, Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, how he spun his academic discoveries out into a biotech company developing new obesity drugs, the need for obesity treatments with fewer side effects than currently available GLP-1 therapies, and the value of pairing scientific leadership with a strong business partner as CEO.
-
BoB Live At BIO: Amber Salzman, Ph.D., Epicrispr Biotechnologies
7/2/2025
This week's episode is one from the road, recorded in front of a live audience in Boston's Seaport neighborhood during the BIO conference (special thanks to MasterControl for making it happen). Amber Salzman, Ph.D., CEO of Epicrispr Biotechnologies (aka 'Epic Bio') explains how epigenetic editing is revolutionizing genetic medicine by controlling gene expression, without cutting DNA like traditional CRISPR technologies.
-
How To Be A Policy Advocate For Biotech With NewYorkBIO's Jennifer Hawks Bland
6/25/2025
On this week's episode of the Business of Biotech, Jennifer Hawks Bland, CEO of NewYorkBIO, shares insights on New York State's life sciences ecosystem while reflecting on her journey from Capitol Hill to biotech advocacy.
-
FDA Trials And Tribulations With Connect Biopharma's Barry Quart
6/19/2025
On this week's episode of the Business of Biotech, Barry Quart, CEO of Connect Biopharma, weighs in on the current state of engagement between drug developers and the FDA, and how that key relationship continues to evolve under new leadership. Barry also discusses moving the company from China to San Diego, why a U.S. financial reporting structure helps attract investors, and how Connect is finding the white spaces in respiratory disease -- the company's lead candidate is a biologic drug targeting acute asthma and COPD exacerbations.
-
Proactive Procurement Strategies For Biotech With Tom Wells
6/12/2025
On this week's episode of the Business of Biotech, Tom Wells, Director of Life Sciences at 4C Associates, reveals why -- and how -- smart procurement practices can make or break emerging biotech companies during critical growth stages. Tom shares insights into procurement tools and strategies that can deliver breakthrough solutions, how poor procurement practices can damage investor confidence, and why thinking about procurement as the front end of demand flow, not the back end of supply chain, can help drug developers avoid costly mistakes.
-
The Discovery Of Microbes And Implications For Public Health Today, With Science Writer Thomas Levenson
6/4/2025
On this week's Business of Biotech, Thomas Levenson, MIT professor and author of So Very Small: How Humans Discovered The Microcosmos, Defeated Germs — And May Still Lose The War Against Infectious Disease talks about what he learned in the writing of So Very Small, how cultural and political forces shape scientific progress, and what it means for drug developers, public health officials, and patients everywhere.
-
Psychedelics For Mental Health Disorders With atai's Srinivas Rao, M.D., Ph.D.
5/28/2025
On this week's Business of Biotech episode, Dr. Srinivas Rao, co-founder and CEO at atai Life Sciences, explains how his engineering background led him to the development of psychedelic compounds for treating depression, anxiety, and other mental health disorders. Internal drug development efforts at atai are focused on short-duration psychedelics that can work within existing healthcare infrastructure, with the potential to transform the treatment of mental health disorders.
-
Biotech Angel Investing With Yaniv Sneor
5/21/2025
On this week's Business of Biotech episode, Yaniv Sneor, founder of the Mid Atlantic Bio Angels and CEO at Native State Therapeutics, explains how life science angel investors evaluate biotech startups, and offers tips for young drug developers in search of funding. The conversation covers how to create a successful pitch, red flags for potential investors, the importance of angel investing syndicates, the sweet spots for exit timelines and funding amounts, and why it still makes sense to invest in biotech over other industry sectors.